Human papillomaviruses (HPVs) are small, nonenveloped DNA viruses which induce warts (papillomas) at cutaneous and mucosal sites (33) . HPVs have also been linked etiologically to invasive carcinoma of the uterine cervix (22, 31) . The virion particle consists of a double-stranded circular DNA genome contained within an icosahedral capsid composed of 72 pentameric capsomeres of the major capsid protein L1 and a small amount of the minor capsid protein L2 (1, 6, 11) . The structures and functions of the L1 and L2 proteins are not well studied because papillomaviruses have not been propagated in tissue culture systems. Recently, several groups have generated virus-like particles (VLPs) from different papillomaviruses by using vaccinia virus, baculovirus, or yeast expression systems to produce L1 alone or in combination with L2 (7, 9, 13, 18, 24, 26, 30, 40, 42, 44) . These reagents are potentially useful for studies of virion structure, virion assembly, and virus-host interactions and are candidates for HPV vaccines.
One important function of the L1 and L2 proteins, which is still poorly understood, is their role as targets of the host immune response. Early studies of antibody response, which used either synthetic peptides derived from the open reading frames of the L1 and L2 genes or bacterially expressed fusion proteins, gave conflicting results (36, 38) . These tests primarily measure antibodies to linear epitopes. Since most of the antibodies elicited by a natural infection are directed to conformational epitopes, tests with peptides and fusion proteins may not be very reliable for the measurement of virus-specific seroreactivity. In contrast, VLPs have been useful as reagents for detecting antivirion antibody responses, suggesting that they possess the conformational epitopes against which the antibody response is directed (3, 4, 14, 23, 25, 27, 41) .
In vitro transcription-translation provides a simple and rapid method for the expression of proteins. In a variety of systems, in vitro-translated proteins have retained the conformational properties required for functional activities such as binding to DNA, enzymatic activity, and formation of multiprotein complexes (5, 10, 12, 20) . In previous studies, we have shown that radioimmunoprecipitation assays (RIPA) with in vitro-translated HPV type 16 (HPV-16) E6 and E7 proteins are an efficient way to measure type-specific antibodies to these proteins (21, 34, 39) . We report here that the HPV-16 L1 capsid protein when transcribed and translated in vitro self-assembles into VLPs with the size and shape of native virions and that it reacts with a majority of sera from women who have a documented infection with HPV-16.
MATERIALS AND METHODS

Construction of recombinant pCITE vector.
A fragment of the HPV-16 L1 gene, from the sixth nucleotide upstream of the second methionine to the stop codon, was prepared by a nested PCR. The outer primers were as follows: 5Ј sense primer, 5Ј-TCCAGGGTCTCCACAATATAC-3Ј, and 3Ј antisense primer, 5Ј-TGTTGCATGACACAATAGTTACAC-3Ј. The inner primers were as follows: EcoRV-extended 5Ј sense primer, 5Ј-AACGTTTACCATGATATCTTTC AGATGTCTCTTTGGCTGCCTAGTGAGG-3Ј (the ATG start codon is in boldface and the EcoRV site is underlined), and XbaI-extended 3Ј antisense primer, 5Ј-GCATTCTAGATTACAGCTTACGTTTTTTGCG-3Ј (the reverse complement of the stop codon is in boldface and the XbaI site is underlined). The primers were used to prepare an HPV DNA template from a cervical sample obtained from a patient with invasive cervical cancer (2) . The sample contained only HPV-16 DNA and was negative for other HPV DNAs as determined by diagnostic PCR with consensus (MY09 and MY11) L1 primers for amplification and an HPV-16 type-specific oligonucleotide probe for detection of HPV-16 amplicons. The cervical sample containing HPV-16 DNA was boiled for 3 min and then cooled rapidly on ice. A 0.5-l aliquot of the sample was used in the PCR. The PCR mixture contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl 2 , 0.2 mM each deoxynucleoside triphosphate, 2.5 U of Taq DNA polymerase, and 1.25 M primers in a 50-l volume. The cycling conditions were set at 30 1-min cycles of denaturation at 94ЊC, reannealing at 55ЊC, and extension at 72ЊC. The final cycle included a 10-min extension at 72ЊC. The product of the first PCR was diluted 1:100 in deionized water, and 5 l of the diluted product was used in the second PCR. Conditions for the second PCR were identical to those for the first PCR. The PCR product was extracted with phenol-chloroform, precipitated in 95% ethanol, and resuspended in Tris-EDTA buffer. The size of the amplified fragment was determined with an ethidium bromide-stained 1% agarose gel, and the DNA was quantitated by UV spectroscopy.
The HPV-16 L1 gene fragment was cloned into a pCITE vector (Novagen Inc., Madison, Wis.). These vectors are designed for efficient in vitro transcription and translation of cloned inserts. They contain a 501-bp encephalomyocarditis virus sequence that increases the translational efficiency of adjacent sequences up to 16-fold in rabbit reticulocyte lysates. Immediately upstream of the encephalomyocarditis virus sequence is a T7 promoter. The PCR-amplified HPV-16 L1 DNA fragment was digested with EcoRV and XbaI and ligated into the corresponding sites in pCITE-2a to create pCITEHPV16L1. The ligation mixture was used to transform NovaBlue competent cells (Novagen, Inc.) according to the manufacturer-specified instructions. Transformed colonies were selected on Luria-Bertani agar plates containing tetracycline (50 g/ml) and carbenicillin (50 g/ml). The clones were expanded by overnight incubation in Luria-Bertani medium containing antibiotics. Plasmid DNA was isolated by using a Qiagen plasmid purification kit (Qiagen, Inc., Chatsworth, Calif.), and plasmids were screened for inserts of the appropriate size by restriction digestion with EcoRV and XbaI.
In vitro transcription and translation. pCITEHPV16L1 DNA was linearized with XbaI, and 1 g of linearized plasmid DNA was transcribed in vitro for 4 h at 37ЊC with the commercially available Megascript transcription kit (Ambion Inc., Austin, Tex.). The reaction mixture was digested with RNase-free DNase and extracted with phenol-chloroform. RNA was precipitated with isopropyl alcohol, washed with 70% ethanol, and resuspended in deionized water. One microgram of RNA was used to program 50 l of micrococcal nuclease-treated rabbit reticulocyte lysate (Promega, Madison, Wis.) in the presence of 40 Ci of [ 35 S]methionine. Radiolabeled proteins were electrophoresed through a sodium dodecyl sulfate (SDS)-4 to 15% gradient polyacrylamide gel and visualized by autoradiography. For preparation of in vitro-translated protein for electron microscopy, radiolabeled methionine was omitted from the lysate.
Transmission electron microscopy. The in vitro-translated lysates were subjected to centrifugation at 110,000 ϫ g for 2.5 h through a 40% (wt/vol) sucrosephosphate-buffered saline (PBS) cushion in an SW50.1 rotor. The resulting pellet was resuspended in 0.01 M ammonium acetate (pH 7.0) with 1% glycerol. The particles were adsorbed onto Formvax carbon-coated grids, stained with 1% ammonium phosphotungstic acid (pH 7.0), and examined at 80 kV on a Philips CM-10 electron microscope at magnifications of ϫ28,500 and ϫ73,000. Baculovirus-expressed HPV-16 L1 VLPs prepared as described previously were processed similarly for electron microscopy (15, 37) .
RIPA. RIPA were performed by a modification of a previously described method (39) . Briefly, 10 l of lysate and 10 l of undiluted serum were incubated in a 200-l volume (final serum dilution, 1:20) containing 10 mM Tris-HCl (pH 8.0), 140 mM NaCl, 0.5 mM CaCl 2 , 0.1% bovine serum albumin, and 0.025% NaN 3 (RIPA buffer) for 4 h at 4ЊC. Ten microliters of monoclonal antibody supernatant (final dilution, 1:20) and 2 l of rabbit polyclonal serum (final dilution, 1:100) were used in a 200-l volume of RIPA buffer. The original protocol was modified by the addition of CaCl 2 and removal of Nonidet P-40 detergent, since the presence of the detergent in the buffer disrupted the assembly of the VLPs. After the initial incubation of serum and lysate, 80 l of washed protein A-Sepharose beads (Pharmacia LKB, Piscataway, N.J.) suspended in RIPA buffer was added, and the mixture was incubated with shaking for an additional 14 h at 4ЊC. The beads were washed six times with RIPA buffer and then resuspended in 50 l of Laemmli sample buffer consisting of 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 25% glycerol, 0.01% bromophenol blue, and 100 mM dithiothreitol. The beads were boiled for 5 min and spun for 5 s at 10,000 ϫ g. The supernatant was loaded onto an SDS-4 to 15% gradient polyacrylamide gel, and radiolabeled proteins were detected by fluorography with Amplify (Amersham, Arlington Heights, Ill.). For tests with mouse monoclonal antibodies, anti-mouse immunoglobulin G agarose beads (Sigma Chemical Co., St. Louis, Mo.) were used. The reactivity of the protein was scored on a scale of 0, 1, 2, 3 and 4, with 0 being the absence of a band and 1 to 4 representing increasing intensities of the band. A gel showing examples of scoring intensities is shown in Fig. 1 .
ELISA. HPV-16 VLPs were prepared from Sf9 insect cells infected with a recombinant baculovirus expressing the L1 or L1 and L2 proteins of HPV-16 (a gift of J. T. Schiller, National Cancer Institute, Bethesda, Md.). VLPs were purified by cesium chloride density gradient centrifugation by the method of Kirnbauer et al. (15) . For ELISA, test wells of a 96-well microtiter plate were coated with 50 l of purified VLPs (10 g of total protein per ml) in PBS, and control wells were coated with particles in 0.06 M carbonate buffer, pH 9.6. Treatment with an alkaline buffer disrupts the particles. Serum samples diluted 1:10 in PBS-0.5% nonfat milk were tested in each of two test and control wells. VLP-reactive antibodies were detected with horseradish peroxidase-conjugated recombinant protein G by using 2,2Ј-azino-bis-3-ethylbenzyl-thiazoline-6-sulfonic acid (ABTS) and hydrogen peroxide substrate solution (Kirkegaard and Perry, Gaithersburg, Md.). The optical density (OD) was read in a microtiter plate reader at 405 nm. The OD of the serum was calculated by subtracting the mean OD (ϫ 1,000) of control wells from the mean OD (ϫ 1,000) of test wells. The cutoff for seropositivity in the assay was an OD of 166 and was based on the mean plus three standard deviations for the 22 negative control sera from children, excluding one outlier.
Serum donors. The serum donors were a subset of college women previously enrolled in a prospective study of HPV infection (16) . The subjects were students between the ages of 18 and 40 years who sought gynecological care at the Women's Health Clinic of the University of Maryland at College Park. The subjects completed a questionnaire that elicited information on sexual history and demographic characteristics and provided cervical scrapes for HPV diagnosis and serum specimens for antibody assays. Exfoliated cervical cells were tested for HPV by PCR with consensus L1 MY09 and MY11 primers (8) . Specimens were scored as strong positives (signal of 4ϩ) or weak positives (signals of 1ϩ, 2ϩ, or 3ϩ) on the basis of the signal strength of an HPV-16 type-specific probe. Serum samples from 22 healthy children (ages 15 to 60 months) sampled as part of a screening program to identify volunteers for phase II testing of new vaccines were used as a negative control group.
Antibodies specific to HPV-16 intact VLPs. HPV-16 VLPs were prepared from Sf9 insect cells infected with a recombinant baculovirus expressing the L1 gene. The recombinant baculovirus was generated in our laboratory by cotransfection of baculovirus DNA with a baculovirus transfer vector containing the L1 gene (a gift of J. T. Schiller, National Cancer Institute) by a modification of method described by Kirnbauer et al. (15) . To prepare polyclonal hyperimmune sera to HPV-16 VLPs, a New Zealand White rabbit was intradermally immunized twice at a 2-week interval with purified intact HPV-16 VLPs mixed with complete and incomplete Freund adjuvants, respectively. Hyperimmune sera were obtained 1 week after the last immunization.
Monoclonal antibodies were prepared by cell fusion between mouse myeloma Sp20.Ag14 cells (American Type Culture Collection, Rockville, Md.) and splenic B cells obtained from BALB/c mice which were previously immunized three times with HPV-16 VLPs together with Titer-Max adjuvant (Vaxcel Inc., Norcross, Ga.) as described elsewhere (19) . Polyethylene glycol 1500 (Boehringer Mannheim) was used to fuse Sp20.Ag14 and spleen cells. Cells secreting HPV-16 antibodies were screened by ELISA with intact HPV-16 VLPs as the antigen, and clones were selected by using semisolid methylcellulose in complete RPMI medium. Cells were grown in Iscove's medium containing 15% fetal bovine serum and 5% hybridoma cloning factor (HCF) (Origen; IGEN, Inc., Rockville, Md.) during cloning (expansion of cells) and in Iscove's medium containing 5% fetal bovine serum and 1% HCF for the production of highconcentration antibodies in the supernatant of the cell culture.
Monoclonal antibody A was shown by VLP ELISA to react only with epitopes on assembled particles. The mean OD was 0.780 in wells containing antigen diluted in PBS (intact particles) compared with a mean OD of 0.056 in wells containing antigen diluted in carbonate buffer (disrupted particles). Monoclonal antibody B reacted predominantly, but not exclusively, with intact particles. The mean ODs were 0.491 in wells containing intact particles and 0.201 in wells containing disrupted particles. The polyclonal antibody reacted with both intact and disrupted particles. The HPV-16 VLPs used as the immunogen were purified from Sf9 cells infected with recombinant baculovirus, which was produced by recombination between linearized Baculogold recombinant baculovirus (Pharmingen, San Diego, Calif.) and recombinant baculovirus transfer vector 114/K containing the wildtype HPV-16 L1 gene, which was kindly provided by J. Schiller, National Cancer Institute (15) . Purified VLPs were examined for the morphologic features of VLPs by electron microscopy as described previously (35) .
Statistical analysis. Odds ratio estimates with 95% confidence intervals were obtained to assess the magnitude of the association between HPV seropositivity determined by RIPA and HPV DNA positivity. A chi-square test for linear trend was used to determine the agreement between ELISA and RIPA values. A Fischer exact probability calculation was used to determine the correlation between viral load and RIPA values.
RESULTS
In vitro expression and characterization of the HPV-16 L1 capsid protein.
The HPV-16 L1 gene from the second methionine was amplified by PCR and cloned into a vector designed for the efficient in vitro translation of cloned inserts. Six nucleotides upstream of the second methionine were included in the cloned HPV sequence in order to preserve the native nucleotide context of the second methionine. A clinical sample was used as a source of template DNA because the cloned HPV-16 reference sequence has been shown to assemble poorly (15) . The coding sequence of the recombinant plasmid downstream of the T7 RNA promoter included a methionine codon and seven additional amino-terminal amino acids provided by the vector sequence and two amino acids of the HPV-16 L1 open reading frame preceding the second methionine. The major in vitro-translated product migrated in an SDS-polyacrylamide gel as a 55-kDa protein, which corresponds to the expected size of the full-length L1 protein ( Fig.  2A) . A minor product of 29 kDa was also detected in the in vitro-translated sample. The identities of the in vitro-translated proteins were confirmed by RIPA with antibodies of known specificities. The 55-kDa protein reacted with two monoclonal antibodies (A and B) that recognize conformational epitopes on assembled HPV-16 VLPs and with a rabbit anti-HPV-16 VLP polyclonal antiserum that recognizes epitopes on assembled and disassembled VLPs (Fig. 2A) . The 55-kDa protein also reacted with two serum samples from women who had an HPV-16 cervical infection and a high titer of antibody to baculovirus-expressed HPV-16 VLPs by ELISA. The 29-kDa species reacted weakly with all of the sera described above. The 55-and 29-kDa proteins did not react with a control serum sample from an uninfected woman.
In order to determine if the immunodominant epitopes are dependent on the conformational state of the in vitro-translated protein, the protein was denatured by being heated at 85ЊC for 15 min in the presence of 0.1% SDS and tested in a RIPA with the monoclonal antibodies (A and B), which react with intact assembled virions, and with the rabbit polyclonal antiserum, which reacts with both intact and disrupted virions. The denatured L1 protein did not react with the monoclonal antibodies but retained its reactivity with the polyclonal antibodies (Fig. 2B) . The two human sera that had high titers of antibody to HPV-16 VLPs and the uninfected control serum did not react with the denatured L1 protein.
Electron microscopy of VLPs. To determine if the L1 protein self-assembled into VLPs, the lysate was centrifuged through a 40% sucrose cushion and the pellet was analyzed by electron microscopy. Spherical VLPs with a diameter ranging from 40 to 60 nm were identified (Fig. 3A) . These particles are consistent with the size and shape of native HPV virions (diameter, 42 to 56 nm). The individual pentameric capsomeres could be identified at higher magnification (Fig. 3A) . Electron micrographs of baculovirus-expressed HPV-16 L1 protein prepared in our laboratory showed both spherical VLPs and tubular structures (diameter, 40 to 50 nm) of variable length (range, 28 to 40 nm) (Fig. 3B) . The tubular structures were absent from the in vitro-translated preparation.
Reactivity of human sera with in vitro-translated L1 proteins. We tested 116 serum samples from college women previously enrolled in a prospective study of HPV infections, as well as 22 sera from children, by RIPA. The reactivity of the protein was scored on a scale of 0, 1, 2, 3, and 4, with 0 being the absence of a band and 1 to 4 representing increasing intensities of the band (Fig. 1) . The highest reactivity was found for the sera of 28 women who had documented exposure to HPV-16. In this group, 97% of the sera had a reactivity of 1 or greater, 89% had a reactivity of 2 or greater, 68% had a reactivity of 3 or greater, and 18% had a reactivity of 4 (Fig. 4) . This pattern of reactivity contrasted sharply with the results for the children's sera; none of the children's sera (0%) were reactive. Women who had a history of other HPV types and women who were negative for HPVs had nearly identical patterns of reactivity, which was lower than that of the HPV-16-positive women but significantly greater than that of the children. The reactivity of antibodies to HPV-16 L1 protein was related to the viral load in HPV-16-positive women; a band intensity of 4 was seen with 5 of 8 (63%) sera from women who had a high viral load (signal of 4ϩ in the PCR assay) and with 0 of 18 (0%) sera from women who had a low viral load (signal of 1ϩ to 3ϩ in the PCR assay). A statistical analysis for correlation between viral load and RIPA positivity gave a P value of 0.0006 by the two-tailed Fischer exact test.
In order to estimate the prevalence of antibodies to HPV-16 by this assay, we arbitrarily called a serum showing a band intensity of 3 or 4 in RIPA antibody positive. The seropositivities for the different groups were as follows: children, 0%; no HPV, 19%; other HPV types, 23.0%; and HPV-16, 68%. As shown in Table 1 , the differences between antibody preva- ELISA values varied over a wide range at each RIPA score, but ODs were generally greater with higher RIPA scores; the mean ODs were 52, 102, 197, 255, and 597, respectively, for RIPA scores of 0, 1, 2, 3, and 4. The proportion of sera positive by ELISA (OD Ͼ 166) rose progressively from 15% for a RIPA score of 0 to 66.6% for a RIPA score of 4 ( Table 2) . A statistical analysis for linear trend in proportions gave a chisquare value of 9.276 with a P value of 0.0023. However, the kappa statistic for correlation between the two assays was 0.12 for 14 sera which were positive by both tests and for 59 sera which were negative by both tests, while 23 sera were positive by RIPA alone and 20 were positive by ELISA alone.
DISCUSSION
In this study we have demonstrated that the HPV-16 L1 protein expressed by in vitro transcription and translation in a rabbit reticulocyte lysate self-assembles into VLPs and reacts with the majority of sera from women with an HPV-16 cervical infection. In vitro expression of the HPV-16 L1 open reading frame from the second methionine yielded two major products, a 55-kDa protein, which is the predicted size of the full-length L1 capsid protein, and a 29-kDa protein. It is unlikely that translation was initiated from the vector methionine, because no product of the expected size (59 kDa) was observed. The 29-kDa protein may be a degradation product of the full-length L1 protein or may represent initiation of translation from an 16 antibodies, indicating that the in vitro translation product is an HPV peptide. The in vitro-translated product assembled into VLPs and retained its conformational epitopes. Both human sera and monoclonal antibodies that recognize intact VLPs were reactive with the in vitro-translated product, and this reactivity was lost when the translated product was heat denatured. As reported by others (12), we found that the L1 protein alone is sufficient for formation of VLPs. Furthermore, since VLPs formed in a cytoplasmic lysate, it appears that nuclear factors are not required for assembly. This finding is consistent with the observation that purified preparations of the major capsid protein of polyomavirus, which shares many features with the L1 protein of HPV, can assemble into VLPs in vitro in simple buffer solutions containing low concentrations of calcium and magnesium salts (17, 28, 29) . Since proteins are not glycosylated in rabbit reticulocyte lysates, glycosylation does not appear to be necessary for L1 viral particle assembly. A previous study using L1 glycosylation-deficient mutants generated in a vaccinia virus expression system also found that glycosylation of L1 is not a prerequisite for assembly of papillomavirus virions (43) . Rod-like structures, which we and others have observed in VLP preparations from short-term cultures of insect cells, were not seen in the particle preparations generated in a rabbit reticulocyte lysate (32, 40) . The reasons for this are not clear but may reflect differences in the concentrations of reactants or the reaction milieu. Alternatively, spherical particles may represent a favored, more viable conformation of capsids during the virus maturation process. This idea is supported by the observation that long-term culture of L1-expressing baculovirus-infected insect cells selects predominantly for spherical rather than rod-like structures (40) .
Radiolabeled in vitro-translated HPV-16 L1 protein could be used in RIPA to measure anticapsid antibodies in human serum samples. Antibodies to the in vitro-translated HPV-16 L1 product in sera of women were significantly associated with the presence of HPV-16 DNA in the genital tracts of these women. The prevalence of antibody in HPV-16 DNA-positive women ranged from 18 to 97%, depending on the cutoff for seropositivity. In contrast, there was no antibody reactivity in the control population of young children (0%). However, the choice of a cutoff point strongly influenced the estimate of seroprevalence in each of the three groups of college women (HPV-16 positive, positive for other HPVs, and no HPV infection). With a band intensity of 3 or 4 used as evidence of antibody to HPV-16, the prevalences were 68, 23, and 19% for the groups with HPV-16, other HPVs, and no HPV, respectively. With a band intensity of 1 or greater used as evidence of antibody positivity, the corresponding prevalences were 96.4, 67.9, and 65%. If the reactivity measured at the band intensity of 1 or greater is considered HPV specific, as suggested by the results for the children's sera, then the prevalence of antibodies reactive to HPV-16 in sexually active college women may be very high. The high prevalence may indicate that the assay detects cross-reactive antibodies elicited by infection with heterologous HPV types or that prior infection with HPV-16 is very common among these women. With a high cutoff for seropositivity, the odds ratio for an association of seropositivity and HPV-16 DNA positivity was 11.31 (95% confidence interval, 3.49 to 38.60).
The results of RIPA with in vitro-translated HPV-16 L1 correlated modestly with the results of ELISA with baculovirus-expressed HPV-16 L1 and L2 proteins. There was a significant increase in seropositivity by RIPA as the ODs in the ELISA increased (chi-square test for linear trend, P ϭ 0.0023), although many serum samples gave discrepant results in the two assays and the kappa statistic in comparison of the two tests was low. Reasons for the discrepancies between the tests may include differences in the assay methods or in the homogeneities of the two antigen preparations. For example, because VLPs were not purified by density gradient centrifugation, some of the in vitro-expressed L1 may be in the form of capsomeres in addition to fully assembled VLPs. Alternatively, the two assays may not be measuring identical antibodies. Additional experiments, including adsorption studies, are needed to resolve this question. However, both assays appear to be specific for detection of HPV-16 antibodies as judged by the strong correlation with HPV infection status.
The amounts of L1 protein generated by in vitro translation are small compared with the amounts produced in baculovirus. However, the availability of a cell-free system that supports assembly of HPV capsid proteins should facilitate studies of capsid assembly. In a cell-free system, the conditions of assembly can be manipulated in ways that are difficult or impossible to do in cellular systems. In addition to its use in RIPA, in vitro-translated L1 protein may be used for studies of virus-cell interactions and for evaluation of anti-HPV therapeutic agents designed to disrupt capsid assembly. For studies that require the production of many different VLPs, in vitro transcriptiontranslation provides a method for producing VLP that is less labor intensive than the use of baculovirus or other eukaryotic expression systems.
